Phase II trial of doxorubicin and gemcitabine in metastatic renal cell carcinoma with sarcomatoid features.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Doxorubicin (Primary) ; Gemcitabine (Primary) ; Filgrastim; Pegfilgrastim
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jan 2013 Biomarkers information updated
- 02 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Nov 2008 Updated from ClinicalTrials.gov record.